The combination of cost discipline, first revenue, clinical progress with Fast Track designation, and a $20M financing that extends runway to 2028 significantly de-risks the near-term outlook. Traders should monitor upcoming clinical data readouts from the ovarian cancer and SCLC trials as key catalysts.
Price Chart
Executive Summary
Allarity Therapeutics reported its 2025 financial results, highlighting a $14.7 million cash position, $320K in license revenue (vs. none in 2024), and a narrowed net loss of $11.2 million (from $25.1 million in 2024) due to cost discipline. The company received FDA Fast Track designation for stenoparib in advanced ovarian cancer and launched a VA-funded Phase 2 trial in small cell lung cancer, while securing a $20 million debt financing in March 2026 to extend its runway into mid-2028.
Key Financial Metrics
Key Facts
- Cash position was $14.7 million as of December 31, 2025, down from $19.5 million in 2024
- Generated $320,000 in license revenue in 2025, first revenue ever, with no revenue in 2024
- Net loss attributable to common stockholders improved to $11.2 million in 2025 from $25.1 million in 2024
- R&D expenses increased slightly to $6.6 million from $6.1 million; G&A expenses dropped sharply to $6.3 million from $11.4 million
- FDA granted Fast Track designation for stenoparib in advanced ovarian cancer
- Launched VA-funded Phase 2 combination trial of stenoparib in recurrent small cell lung cancer
- Closed $20 million non-convertible debt financing in March 2026, extending cash runway into mid-2028
Financial Impact
Reduced cash burn by ~$2.4 million YoY; added $20M in new debt financing; first-ever revenue of $320K
Risk Factors
- High reliance on stenoparib's clinical success in ovarian cancer and future regulatory approvals
- Debt financing increases financial obligations, though non-convertible structure avoids immediate dilution
- Market cap remains low at $17M, indicating high risk perception despite improved fundamentals
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3265381 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 26d ago | 8-K | $1.04 | awaiting T+20 | — | $0.9000 (−13.46%) |
Sep 29, 2026 28d ago | 8-K | $0.9651 | awaiting T+20 | — | $0.9000 (−6.75%) |
Sep 28, 2026 29d ago | Press Release | $0.9684 $0.9151 | ▼ −5.50% | ▼ −5.47% | $0.9000 (−7.06%) |
Sep 16, 2026 5w ago | 8-K | $1.16 $0.8699 | ▼ −24.68% | ▼ −27.86% | $0.9000 (−22.08%) |
Sep 14, 2026 6w ago | 8-K | $1.17 $0.8601 | ▼ −26.49% | ▼ −28.75% | $0.9000 (−23.08%) |
Sep 11, 2026 6w ago | Press Release | $1.22 $0.9900 | ▼ −18.85% | ▼ −20.72% | $0.9000 (−26.23%) |
Aug 14, 2026 10w ago | Press Release | $1.37 $1.17 | ▼ −14.60% | ▼ −12.61% | $0.9000 (−34.31%) |
Jul 1, 2026 16w ago | 8-K | $1.33 $1.16 | ▼ −12.78% | ▼ −10.60% | $0.9000 (−32.33%) |
Jun 22, 2026 18w ago | 8-K | $1.36 $1.19 | ▼ −12.50% | ▼ −12.35% | $0.9000 (−33.82%) |
Jun 18, 2026 18w ago | Press Release | $1.43 $1.17 | ▼ −18.18% | ▼ −18.71% | $0.9000 (−37.06%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers